Versant Venture Capital II, LP

This profile gathers the share dealings of Versant Venture Capital II, LP across 3 companies, led by Kythera Biopharmaceuticals Inc, Helicos Biosciences Corp and Alexza Pharmaceuticals Inc. We count 32 filings; the first trade dates from 13 March 2006 and the latest from 3 October 2013.

The open-market record is one-sided, with 5 purchases worth €1.2M and not one sale. The totals exclude 3 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 3 share grants and 3 option exercises.

Most recently, on 7 October 2013, the filings show a transaction in Kythera Biopharmaceuticals Inc. The most recent open-market purchase was published on 21 September 2009, 6,258 days ago. Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.